| Literature DB >> 28498934 |
Li-Shiun Chen1, Laurie Zawertailo2, Thomas M Piasecki3, Jaakko Kaprio4, Marilyn Foreman5, Hannah R Elliott6, Sean P David7, Andrew W Bergen8, James W Baurley8, Rachel F Tyndale9, Timothy B Baker10, Laura J Bierut1, Nancy L Saccone11.
Abstract
Implications: This article outlines a framework for the consistent integration of biological data/samples into smoking cessation pharmacotherapy trials, aligned with the objectives of the recently unveiled Precision Medicine Initiative. Our goal is to encourage and provide support for treatment researchers to consider biosample collection and genotyping their existing samples as well as integrating genetic analyses into their study design in order to realize precision medicine in treatment of nicotine dependence.Entities:
Mesh:
Year: 2018 PMID: 28498934 PMCID: PMC5896450 DOI: 10.1093/ntr/ntx097
Source DB: PubMed Journal: Nicotine Tob Res ISSN: 1462-2203 Impact factor: 4.244